Skip to main content
OpenTrials

Clinical trial condition

Triple Negative Breast Cancer

Explore clinical trials studying Triple Negative Breast Cancer. Study availability and eligibility vary by location and protocol.

298 public trials 111 recruiting studies
Refine in advanced search Browse all conditions

Triple Negative Breast Cancer trial results

Active, not recruiting

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

NCT03891953

Conditions
Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, +33 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
  • Novartis Investigative Site Dresden, Saxony, Germany
View Trial Details
Active, not recruiting

Ribociclib and Bicalutamide in AR+ TNBC

NCT03090165

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
Locations
  • University of Illinois Cancer Center Chicago, Illinois, United States
  • Michigan State University Lansing, Michigan, United States
  • Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
  • University of Rochester Medical Center Rochester, New York, United States
View Trial Details
Active, not recruiting

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NCT03983954

Conditions
Adenocarcinoma, Adenocarcinoma Of Esophagus, Adenoma, +79 more
Locations
  • Shalby Hospital Ahmedabad, Gujarat, India
  • National Cancer Institute Jhajjar, Haryana, India
  • All India Institute of Medical Sciences New Delhi, India
  • PMCH (Pacific Medical College & Hospital) Udaipur, Rajasthan, India
View Trial Details
Active, not recruiting

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

NCT04180371

Conditions
Adnexal Diseases, Advanced Solid Tumor Historically Known for High EphA2 Expression, Breast Diseases, +49 more
Locations
  • California Cancer Associates for Research and Excellence, Inc. Encinitas, California, United States
  • University of California - Irvine Medical Center Orange, California, United States
  • Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States
  • Florida Cancer Specialists Sarasota, Florida, United States
View all 28 locations
View Trial Details
Active, not recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +6 more
Locations
  • Alaska Oncology and Hematology Anchorage, Alaska, United States
  • Arizona Oncology Associates, PC-Hope,1845 W Orange Grove Rd Tucson, Arizona, United States
  • Arizona Oncology Associates, PC-Hope,2070 W. Rudasill Rd. Tucson, Arizona, United States
  • Arizona Oncology Associates, PC-Hope Tucson, Arizona, United States
View all 504 locations
View Trial Details
Active, not recruiting

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960

Conditions
Adenocarcinoma, Adnexal Diseases, Breast Diseases, +68 more
Locations
  • Exelixis Clinical Site #53 Gilbert, Arizona, United States
  • Exelixis Clinical Site #18 Phoenix, Arizona, United States
  • Exelixis Clinical Site #1 Duarte, California, United States
  • Exelixis Clinical Site #20 La Jolla, California, United States
View all 124 locations
View Trial Details

Related conditions